… for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). However,
chemotherapy resistance limits our ability to effectively treat advanced lung cancer. Some …

Non-small cell lung cancer (NSCLC), which represents 80–85% of lung cancer cases, is
one of the leading causes of human death worldwide. The majority of patients undergo an …

… Multi-drug chemotherapy resistance in non–small cell lung cancer tumor cultures is common,
and associations between molecular markers and in vitro chemotherapy resistance are …

… of human cancers including lung cancer. Defects … lung tumors to radiation therapy. Here,
we will review clinically relevant mechanisms affecting resistance and sensitivity of lung cancer …

… the most common lung cancer subtypes. … resistance to cisplatin-based chemotherapy, and
we identified LUBAC-mediated NF-κB signaling as a determinant of chemotherapy resistance …

… on drug resistance in small cell lung cancer chemotherapy. Asian Pac J Cancer Prev 2012;
… in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J …

… associated with resistance to neoadjuvant chemotherapy and poor clinical outcomes. Our
findings delineate a crucial role for TLR7 in lung cancer physiopathology. Cancer Res; 74(18); …

… ; however, little is known of the prevalence of extreme chemotherapy drug resistance for …
chemotherapy toxicity. This study describes the prevalence of in vitro chemotherapy resistance …

… a number of lung cancer cell lines with different p53 status were transfected with wild-type
p53 in order to determine the role of p53 in the development of drug resistance. Many groups …

… shown to improve cisplatin chemotherapy by suppressing tumor … potentiates cisplatin
chemotherapy in a lung cancer model. … Rev7 is an attractive strategy to improve chemotherapy. …